Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | ADH1B | P00325 | 1/20 | 0.39 |
| ▸ | ADH1C | P00326 | 1/20 | 0.39 |
| ▸ | ADH1A | P07327 | 1/20 | 0.39 |
| ▸ | ADH4 | P08319 | 1/20 | 0.39 |
| ▸ | ADH7 | P40394 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclohexane SCHEMBL1245819 | 1.00 | EPHX1 (0.50) | EPHX1HPGDKMT2AEPHX2ALOX5 | |
| Cyclohexane SCHEMBL7088247 | 1.00 | EPHX1 (0.50) | EPHX1HPGDKMT2AEPHX2ALOX5 | |
| SCHEMBL31332587 | 1.00 | EPHX1 (0.50) | EPHX1HPGDKMT2AEPHX2ALOX5 | |
| SCHEMBL28568368 | 1.00 | EPHX1 (0.50) | EPHX1HPGDKMT2AEPHX2ALOX5 | |
| Cyclohexane SCHEMBL7091110 | 1.00 | EPHX1 (0.50) | EPHX1HPGDKMT2AEPHX2ALOX5 | |
| SCHEMBL363901 | 1.00 | EPHX1 (0.50) | EPHX1HPGDKMT2AEPHX2ALOX5 | |
| Cyclohexane SCHEMBL1245516 | 1.00 | EPHX1 (0.50) | EPHX1HPGDKMT2AEPHX2ALOX5 | |
| Cyclohexane SCHEMBL14673180 | 1.00 | EPHX1 (0.50) | EPHX1HPGDKMT2AEPHX2ALOX5 | |
| Cyclohexane SCHEMBL11035387 | 1.00 | EPHX1 (0.50) | EPHX1HPGDKMT2AEPHX2ALOX5 | |
| SCHEMBL1228532 | 1.00 | EPHX1 (0.50) | EPHX1HPGDKMT2AEPHX2ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120157876-A | Method for recycling waste polyamide into high value-added product | 浙江理工大学 | 2025-06-17 | — | — | CN | claimed |
| CN-120157876-A | Method for recycling waste polyamide into high value-added product | 浙江理工大学 | 2025-06-17 | — | — | CN | disclosed |
| CN-120157848-A | Method for recycling polyester plastics based on one-pot ring-opening copolymerization and recycled polyester | 浙江理工大学 | 2025-06-17 | — | — | CN | disclosed |
| EP-2812321-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL MYERS SQUIBB CO (US) | 2016-01-06 | — | — | EP | disclosed |
| US-8841331-B2 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2366704-B1 | Inhibitors of serine proteases | VERTEX PHARMA (US) | 2013-10-23 | — | — | EP | disclosed |
| EP-2631238-A1 | Spirocyclic inhibitors of serine proteases for the treatment of hcv infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-28 | — | — | EP | disclosed |
| WO-2013119542-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-15 | — | — | WO | disclosed |
| US-20130203747-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | GILEAD SCIENCES, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203758-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-08-08 | — | — | US | disclosed |
| US-8097728-B2 | Iminosugar compounds with antiflavirus activity | PHILADELPHIA HEALTH & EDUCATION CORPORATION (US) | 2012-01-17 | — | — | US | disclosed |
| EP-1917269-B1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMA (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-28 | — | — | US | disclosed |
| US-20090042268-A1 | IMINOSUGAR COMPOUNDS WITH ANTIFLAVIRUS ACTIVITY | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-02-12 | — | — | US | disclosed |
| WO-2008106139-A1 | INHIBITORS OF SERINE PROTEASES FOR THE TREATMENT OF HCV INFECTIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-04 | — | — | WO | disclosed |
| US-7176214-B2 | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203758-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, SLC10A1, HCCS | EPHX1 2368/4885HPGD 1433/4885KMT2A 4752/4885 |
| US-20090042268-A1 | IMINOSUGAR COMPOUNDS WITH ANTIFLAVIRUS ACTIVITY | INSRR, RNASEL, AGL | EPHX1 4804/4885HPGD 3945/4885KMT2A 4609/4885 |
| US-20130203747-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | RTF2, REV1, RTF1 | EPHX1 3083/4885HPGD 1845/4885KMT2A 2329/4885 |
| US-20110182856-A1 | INHIBITORS OF SERINE PROTEASES | PRSS1, SPINT2, PRSS2 | EPHX1 1623/4885HPGD 1824/4885KMT2A 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.